Physician profile
John D Moore
NPI 1174707897
$6,036.21
in general payments reported to CMS, 2019-2025
34 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $208 · 2021: $682 · 2022: $839 · 2023: $1,443 · 2024: $1,353 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,283.28 | 2019-2025 | |
| Janssen Biotech, INC. | $739.99 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $620.57 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $371.47 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Pfizer INC. | $320.62 | 2019-2025 | |
| Braintree Laboratories, INC. | $237.45 | 2020-2022 | |
| Olympus America INC. | $217.71 | 2019-2024 | Disposable Grasping Forceps, Disposable Biopsy Forceps, Endoclot Phs |
| Lilly USA, LLC | $165.36 | 2023-2025 | Omvoh |
| Genzyme Corporation | $161.32 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $106.07 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $99.63 | 2019-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $96.57 | 2021-2025 | Tremfya |
| Qol Medical, LLC | $94.35 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $61.50 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $57.86 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.11 | 2023 | Amjevita, Avsola |
| Organon LLC | $56.68 | 2023-2024 | Renflexis |
| Ardelyx, INC. | $40.17 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $28.01 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $26.33 | 2021-2023 | |
| Allergan, INC. | $24.14 | 2020 | |
| Enterra Medical, INC. | $20.39 | 2023 | |
| Orphalan INC | $16.82 | 2025 | Cuvrior |
| Medtronic, INC. | $16.79 | 2023 | Interstim |
| Capsovision, INC. | $16.09 | 2023 | Capsocam Plus |
| Alnylam Pharmaceuticals INC. | $15.57 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2021 | |
| Celgene Corporation | $13.79 | 2021 | |
| Daiichi Sankyo INC. | $13.61 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $12.93 | 2022 | |
| Novo Nordisk INC | $11.96 | 2019 | |
| Genentech USA, INC. | $11.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $5.72 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,706.11 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.